Organovo is a biotech platform company that has developed a leadership position with its revolutionary ability to 3D bioprint tissues with human functionality. We are pursuing multiple IND-track programs to develop our NovoTissues® implantable tissues to address a number of serious unmet medical needs in adult and pediatric populations, initially focusing on liver disease. Our first IND-track program for Alpha-1-antitrypsin deficiency recently received orphan drug designation from the FDA, and we expect to file our first IND in 2020. In order to help fund our plan to initiate multiple IND-track programs, we are providing access to our ExVive™ in vitro tissue disease modeling platform to facilitate high value drug discovery and development collaborations. Organovo’s wholly-owned subsidiary, Samsara Sciences, Inc. provides the Company and its clients with high quality human liver and kidney cells for research applications.
Want to be notified of what’s happening at Organovo? Join Our Talent Network
Talent Networks enhance your job search. Whether you choose to apply or just leave your information, we look forward to staying connected with you.
By joining you will receive alerts with new job opportunities and company announcements that match your interests. You can also share job opportunities and announcements through social media or email.